My laboratory applies genetics and genome science to drug discovery and development. We integrate molecular and computational tools for drug pathway discovery, target validation and biomarker discovery. The team uses a range of tools in human genetics and genomics, including high-throughput gene expression, microarrays and next-generation sequencing.

A current focus of the team is nucleic acid–based therapeutics that directly impact RNA splicing and stability. Our goal is to use global transcriptome analysis to better understand how naturally occurring and synthetic ncRNAs or antisense oligonucleotides modulate gene expression. Many of these efforts are concentrated in neurodegenerative diseases with defective RNA processing. We collaborate with colleagues in Biogen therapeutic areas to translate our observations into biomarkers of disease activity and drug action.

Another focus of the team is applications of human genetics to drug target discovery and patient stratification. We seek to discover novel genetic associations with disease or drug response, and to unravel the biology of known and novel genetic variants. These studies increasingly rely on integrating genomic, transcriptomic and clinical data. By working closely with clinical researchers and computational biologists, we aim to translate basic research discoveries into new drug targets and biomarkers.

Education

  • Postdoctoral Fellow, Harvard University, Cambridge, MA, 1993
  • Ph.D., Washington University, St. Louis, MO, 1993
  • M.S., Rutgers University, New Brunswick, NJ, 1987
  • B.S., Rutgers University, New Brunswick, NJ, 1984

Selected Publications

See more scientists